Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Ear Nose Throat J ; 95(2): 70-2, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26930332

ABSTRACT

Methylene blue has been safely used for the localization of parathyroid glands during parathyroidectomy, and only a few adverse effects have been documented. Methylene blue administration as a cause of pulse-oximetry-related skin injury is extremely rare. We describe 2 such cases in patients who developed a blister on the second digit at the pulse oximetry site after an uncomplicated excision of a parathyroid adenoma. In another case, a patient became bradycardic intraoperatively; she was successfully resuscitated, but she incurred a second-degree burn at the pulse oximetry site. In all 3 cases, the burns resolved with local wound care. We publish this report to alert surgeons and anesthesiologists to the risk of skin complications with the use of high-dose intraoperative methylene blue.


Subject(s)
Burns, Chemical/etiology , Finger Injuries/chemically induced , Methylene Blue/adverse effects , Oximetry/adverse effects , Parathyroidectomy/adverse effects , Postoperative Complications , Adenoma/surgery , Adult , Aged , Female , Humans , Middle Aged , Parathyroid Neoplasms/surgery
2.
J Biol Chem ; 284(4): 2080-7, 2009 Jan 23.
Article in English | MEDLINE | ID: mdl-19017630

ABSTRACT

Overexpression of the receptor tyrosine kinase erbB2 (Her2 in humans) is correlated with a poor prognosis in breast and ovarian cancers. Treatment with trastuzumab (a monoclonal antibody against erbB2) improves survival; however, it also causes cardiomyopathy. We hypothesized that blockade of the erbB2 receptor induces cardiomyocyte death through a mitochondrial pathway that is dependent on the production of reactive oxygen species (ROS). We first showed that levels of erbB2 receptor are significantly decreased in an animal model of ischemic heart disease and in human ischemic cardiomyopathy. We treated neonatal rat cardiomyocytes with an inhibitory erbB2 antibody to study the mechanism behind the deleterious effects of erbB2 blockade. These cells displayed a dose-dependent increase in ROS production and cell death compared with control IgG-treated cells; these processes were reversed by the antioxidant, N-acetylcysteine. The effects of erbB2 antibody on both cell death and ROS production were also reversed by cyclosporine A and diazoxide, chemicals that regulate the pro- and anti-apoptotic channels in the mitochondria, respectively. Furthermore, mouse embryonic fibroblasts lacking Bax and Bak (proteins that mediate cell death through a mitochondrial pathway) were resistant to the deleterious effects of erbB2 antibody. These effects of erbB2 blockade appear to occur through a pathway involving AKT and PKC-alpha. Our results suggest that erbB2 plays a role in cardiomyocyte survival, and that the deleterious effects of trastuzumab on the heart occur through a mitochondrial pathway and is mediated by ROS production. Manipulation of redox signaling may be beneficial in cancer patients receiving trastuzumab.


Subject(s)
Mitochondria/metabolism , Myocytes, Cardiac/cytology , Myocytes, Cardiac/metabolism , Reactive Oxygen Species/metabolism , Receptor, ErbB-2/antagonists & inhibitors , Receptor, ErbB-2/metabolism , Signal Transduction/drug effects , Animals , Antibodies/immunology , Cell Death , Dogs , Gene Expression Regulation, Enzymologic/drug effects , Humans , Mitochondria/drug effects , Myocardial Ischemia/enzymology , Myocardial Ischemia/genetics , Myocardial Ischemia/pathology , Myocytes, Cardiac/drug effects , Protein Kinase C-alpha/metabolism , Proto-Oncogene Proteins c-akt/metabolism , RNA, Small Interfering/genetics , Receptor, ErbB-2/genetics , Receptor, ErbB-2/immunology , Time Factors
3.
Dermatol Surg ; 34 Suppl 1: S40-7, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18547180

ABSTRACT

BACKGROUND First impression is influenced by facial appearance and improved by cosmetic surgery. OBJECTIVE We wanted to determine if treatment with botulinum toxin A (BTxnA) would improve first impression. MATERIALS AND METHODS Women received BTxnA in the forehead. Photos were taken prior to, and 1 week after, final BTxnA injection in smiling and relaxed poses. Photos were divided into books with each subject represented only once. Evaluators completed a survey rating first impression on various measures of success for each photo. RESULTS No differences were seen for social skills, financial, or relationship success scales. A significant decrease in first impression scores between treatment photos was seen for academic performance and occupational success. However, analysis of between-subject effects found that "smile/relax" accounted for the decreased score in both scales. Significant increases in first impression scores were seen for dating success, attractiveness, and athletic success scales where smile/relax and BTxnA contributed significantly to the improved scores. CONCLUSIONS BTxnA improved first impression scores for dating success, attractiveness, and athletic success scales. Academic performance and occupational success scores were not affected by BTxnA when the smile/relax variable was included. The smile/relax variable was a more important predictor for academic performance and occupational success scores.


Subject(s)
Botulinum Toxins, Type A/administration & dosage , Cosmetic Techniques/psychology , Esthetics , Forehead , Neuromuscular Agents/administration & dosage , Social Perception , Analysis of Variance , Female , Humans , Injections, Intramuscular , Interpersonal Relations , Middle Aged , Photography , Self Concept , Skin Aging , Surveys and Questionnaires
SELECTION OF CITATIONS
SEARCH DETAIL
...